Pancreatic Neoplasms: Benign and Malignant
Conditions
Interventions
Telesurgery Group:Performance of Robotic Teleoperative Pancreatic Surgery
Sponsors
Chinese People’s Liberation Army General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Obtain informed consent for telesurgical robotic procedures signed by the patient or their legal representative; 2. Compliance with the study protocol and follow-up procedures; 3. Patients aged >=18 and = 9.0 g/dL (may be maintained or achieved via blood transfusion); 7. Absolute neutrophil count >=1.5×10^9(/L; 8. Platelet count >=50×10^9/L; 9. Serum creatinine =60 mL/min; 10. For patients not receiving anticoagulant therapy, prothrombin time international normalized ratio (INR) <=1.5 and activated partial thromboplastin time (APTT) <=1.5 × ULN. Patients on full-dose or parenteral anticoagulation may be enrolled if the anticoagulant dose has been stable for at least two weeks prior to study entry and coagulation test results are within the therapeutic range required for local treatment; 11. Women of childbearing potential (aged 15–49) must have a negative urine pregnancy test within 7 days before initiating treatment.
Exclusion criteria
Exclusion criteria: 1. Diagnosis of malignant tumors at other sites within the past 5 years; or presence of brain, lung, bone metastases, or abdominal lymph node metastasis; 2. Severe cardiopulmonary, hepatic, or renal insufficiency; 3. Pregnant or lactating women; 4. Any condition that may compromise patient safety or study data integrity, including significant medical risk factors, medical disorders, or laboratory abnormalities; 5. HIV or syphilis infection; 6. Investigator’s judgment that the patient is unsuitable for participation in this trial; 7. Unwillingness or inability to comply with study procedures, or anticipated absence from observation for one or more treatment cycles during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Intraoperative Blood Loss;Operative Time;Pancreatic Fistula Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative Complication Rate;Length of Postoperative Hospital Stay;Reoperation Rate;90-Day Mortality Rate; | — |
Countries
China
Contacts
Public ContactZhiming Zhao
Chinese People’s Liberation Army General Hospital
Outcome results
None listed